PRQR has been the topic of several other research reports. Chardan Capital reaffirmed a neutral rating and issued a $2.00 target price on shares of ProQR Therapeutics in a report on Friday, August 4th. HC Wainwright reissued a buy rating and set a $5.00 price objective on shares of ProQR Therapeutics in a report on Monday, August 7th. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat, ProQR Therapeutics presently has an average rating of Moderate Buy and a consensus price target of $3.88.
ProQR Therapeutics Stock Down 4.3 %
ProQR Therapeutics (NASDAQ:PRQR – Get Free Report) last issued its earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, beating the consensus estimate of ($0.12) by $0.01. The firm had revenue of $1.31 million for the quarter, compared to analysts’ expectations of $2.77 million. ProQR Therapeutics had a negative net margin of 1,427.27% and a negative return on equity of 86.23%. As a group, equities research analysts predict that ProQR Therapeutics will post -0.25 earnings per share for the current fiscal year.
Hedge Funds Weigh In On ProQR Therapeutics
Hedge funds have recently modified their holdings of the business. Belvedere Trading LLC purchased a new position in shares of ProQR Therapeutics during the fourth quarter worth approximately $42,000. Tower Research Capital LLC TRC grew its position in shares of ProQR Therapeutics by 164.8% during the first quarter. Tower Research Capital LLC TRC now owns 14,132 shares of the biopharmaceutical company’s stock worth $30,000 after acquiring an additional 8,796 shares during the last quarter. Mariner LLC purchased a new position in shares of ProQR Therapeutics during the fourth quarter worth approximately $68,000. Two Sigma Securities LLC purchased a new position in shares of ProQR Therapeutics during the first quarter worth approximately $41,000. Finally, Vanguard Personalized Indexing Management LLC purchased a new position in shares of ProQR Therapeutics during the fourth quarter worth approximately $79,000. 26.15% of the stock is currently owned by hedge funds and other institutional investors.
ProQR Therapeutics Company Profile
ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).
- Five stocks we like better than ProQR Therapeutics
- Best Stocks Under $5.00
- 2 Recession-Proof Intelligence Stocks to Defend Your Portfolio
- What is the Australian Securities Exchange (ASX)
- 5 Reasons Mullen Automotive is About to Turn a Corner
- Stocks in the Dow: About the Dow Jones Industrial Average (DJIA)
- Qualcomm and Apple Forge Ahead with New Modem Partnership
Receive News & Ratings for ProQR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProQR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.